Neurotensin: A Novel Mediator of Ovulation
神经降压素:一种新型的排卵调节剂
基本信息
- 批准号:10011839
- 负责人:
- 金额:$ 67.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-06 至 2024-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAnimal ModelAntibodiesBioinformaticsCell physiologyComplementDataDefectDevelopmentEGF geneEndothelial CellsEvaluationEventFailureFc ReceptorFemale Contraceptive AgentsFemale infertilityFertilityFertilizationFutureGene Expression ProfilingGenesGonadotropinsHistologicHumanHuman Chorionic GonadotropinIn VitroInfertilityInjectionsLH ReceptorsLuteinizationMediatingMediator of activation proteinMessenger RNAModelingMonkeysMotionMusNeuraxisNeuropeptidesNeurotensinNeurotensin ReceptorsNew AgentsOocytesOvarianOvarian FollicleOvarian TissueOvaryOvulationPathway interactionsPlayPregnancyPregnancy OutcomeProcessProgesteroneProstaglandinsReceptor SignalingRegulationReproductive ProcessReproductive systemRodentRoleRuptureSignal TransductionSystemTechnical ExpertiseTestingTimeVascular Endothelial CellWild Type MouseWomanangiogenesisbasecell typecollaborative approachdifferential expressionexperimental studyfemale fertilitygranulosa cellimplantationimproved outcomein vitro Modelin vivomouse modelneutralizing antibodynonhuman primatenoveloocyte qualityparacrinepreventreceptorreceptor expressionreproductive functionreproductive successresponsetheca celltranslational model
项目摘要
A woman’s fertility is dependent on the cascade of events leading up to ovulation. Defects in this ovulatory
process result in 25% of all female infertility cases, supporting the paramount role of ovulation in reproductive
success and providing a strong premise to explore mediators of the ovulatory process. We propose that
neurotensin is one of these pivotal regulators of the ovulatory process.
Ovulation is set in motion by the preovulatory LH surge which increases ovarian intrafollicular mediators
that act to bring about oocyte release. Our novel and exciting preliminary data indicate that neurotensin (NTS),
a small neuropeptide, is a key intrafollicular mediator of ovulation. This is based upon our findings that NTS is
one of the most differentially-expressed genes in the granulosa cells of the human ovulatory follicle, up to
15,000 fold after the ovulatory gonadotropin surge. Likewise, LH also rapidly and significantly increases NTS
mRNA in granulosa cells from rodent and monkey ovulatory follicles. Importantly, injection of a neurotensin
antibody into monkey preovulatory follicles blocked oocyte release resulting in luteinized unruptured follicles,
consistent with failure of ovulation. Similarly, mice lacking NTS expression form luteinized unruptured follicles
following LH/hCG administration, and a NTS receptor antagonist inhibits oocyte release in a novel in vitro
model of mouse ovulation. Yet, other than our preliminary data, nothing is known regarding the temporal
expression of NTS receptors or the function of NTS in ovulation and female fertility. These questions will be
addressed in this proposal through a collaborative approach utilizing the exceptional backgrounds, technical
expertise, and models of the Project Leaders. We will make use of a high-impact, translational model where
the granulosa and theca from human periovulatory follicles will be collected prior to and at three designated
times after hCG (early, late and postovulatory) to complement in vivo and in vitro studies performed with mice
and monkeys. The regulation of NTS and NTS receptor expression in the ovulatory follicle will be illuminated
and compared across women, monkeys and mice in Aim 1. The ovulatory functions stimulated by NTS in
granulosa, theca, cumulus, and endothelial cells of the follicle will be elucidated in Aim 2. The actions of NTS
on ovulation, as well as other key reproductive processes, will be revealed in mice and monkeys using mice
lacking NTS expression, NTS receptor antagonists, and NTS-neutralizing antibodies in Aim 3. A major strength
of this proposal is the collaborative interactions between Dr. Curry and Dr. Duffy to address the function of NTS
and its receptors in periovulatory events across multiple species, including exceptional human ovarian tissues
and in vivo studies of non-human primates, an animal model with high relevance to human reproductive
function. Thus, there is an exceptional degree of significance in understanding the basic tenets of oocyte
release which provides a fundamental platform to either improve outcomes for infertile women or conversely
provide targets to prevent oocyte release for female contraception.
女人的生育能力取决于导致排卵的一系列级联。这种排卵中的缺陷
过程导致所有女性不育病中有25%,支持排卵在生殖中的重要作用
成功并提供了有力的前提来探索排卵过程的介体。我们提出了这一点
神经素是排卵过程的这些关键调节剂之一。
排卵前LH激增促进排卵,从而增加卵巢内介质
这种行为是为了释放卵母细胞。我们的新颖而令人兴奋的初步数据表明神经素(NTS),
小神经肽是排卵的关键内部介体。这是基于我们的发现,即NTS是
人排卵叶的颗粒细胞中最差异表达的基因之一,
排卵性促性腺激素激增后15,000倍。同样,LH也迅速而显着增加了NT
来自啮齿动物和猴子排卵卵泡的颗粒细胞中的mRNA。重要的是,注射神经蛋白
进入猴子前卵泡中的抗体阻塞卵母细胞释放,导致黄体未破裂的卵泡,
与排卵失败一致。同样,缺乏NTS表达的小鼠形成了黄体化卵泡
在LH/HCG给药后,NTS受体拮抗剂抑制了新型体外卵母细胞的释放
小鼠排卵模型。但是,除了我们的初步数据外,有关临时性的尚无
NTS受体的表达或NTS在排卵和女性生育中的功能。这些问题将是
通过采用特殊背景的协作方法在本提案中解决,技术
专业知识和项目负责人的模型。我们将利用一个高影响的,翻译的模型
将在指定之前和三个
在HCG(早期,晚期和分解后)后完成体内和体外研究后进行小鼠进行的时代
和猴子。排卵叶中NTS和NTS受体表达的调节将被照亮
并在AIM 1中进行比较,猴子和小鼠在AIM 1中进行比较。
将植物的颗粒,theca,积云和内皮细胞在AIM 2中阐明。NTS的作用
在排卵以及其他关键的生殖过程中,将在小鼠和猴子中揭示使用小鼠
在AIM 3中缺乏NTS表达,NTS受体拮抗剂和NTS中和抗体。
该建议的是库里博士和达菲博士之间的协作互动,以解决NTS的功能
及其在跨多种物种(包括特殊人类卵巢组织)的期次培养物中的受体
和非人类灵长类动物的体内研究,这是一种与人类生殖高相关的动物模型
功能。这在理解卵母细胞的基本宗旨方面具有非凡的重要性
发布提供了一个基本平台,可以改善不育女性的预后或相反
提供靶标,以防止卵母细胞释放女性违规。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas E Curry其他文献
Thomas E Curry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas E Curry', 18)}}的其他基金
Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划:培训下一代女性健康学者
- 批准号:
10428147 - 财政年份:2022
- 资助金额:
$ 67.55万 - 项目类别:
Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划:培训下一代女性健康学者
- 批准号:
10858550 - 财政年份:2022
- 资助金额:
$ 67.55万 - 项目类别:
Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划:培训下一代女性健康学者
- 批准号:
10649610 - 财政年份:2022
- 资助金额:
$ 67.55万 - 项目类别:
Supplement for Kentucky BIRCWH Program: Training the Next Generation of Women's Health Scholars
肯塔基州 BIRCWH 计划补充材料:培训下一代女性健康学者
- 批准号:
10682952 - 财政年份:2022
- 资助金额:
$ 67.55万 - 项目类别:
Center for Appalachian Research in Environmental Sciences-Pilot Project Program (PPP)
阿巴拉契亚环境科学研究中心试点项目计划 (PPP)
- 批准号:
10610036 - 财政年份:2017
- 资助金额:
$ 67.55万 - 项目类别:
Ovulation and Luteal Formation in Rodents Monkeys and Women
啮齿动物、猴子和女性的排卵和黄体形成
- 批准号:
9325047 - 财政年份:2014
- 资助金额:
$ 67.55万 - 项目类别:
Ovulation and Luteal Formation in Rodents Monkeys and Women
啮齿动物、猴子和女性的排卵和黄体形成
- 批准号:
8609207 - 财政年份:2014
- 资助金额:
$ 67.55万 - 项目类别:
相似国自然基金
新型IL2Rβγ激动剂逐级控释联合放疗对抗三阴性乳腺癌的作用及机制研究
- 批准号:82303819
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
负载自组装型非核苷类STING激动剂的亚精胺水凝胶用于抗肿瘤免疫治疗及机制研究
- 批准号:82303561
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向SIRT3小分子激动剂调控三阴性乳腺癌细胞自噬和免疫微环境的机制研究
- 批准号:82373193
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于OSMAC-GNPS分析策略的蚂蚱内生真菌Aspergillus sp.中新颖泛PPAR激动剂的发现及治疗NASH研究
- 批准号:82304340
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
探究FSP1激动剂在治疗肾缺血再灌注损伤中的分子机理与应用
- 批准号:82304600
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Dravet Syndrome Anti-Epileptic Control by Targeting GIRK Channels
通过针对 GIRK 通道进行 Dravet 综合征抗癫痫控制
- 批准号:
10638439 - 财政年份:2023
- 资助金额:
$ 67.55万 - 项目类别:
Illumination of TAAR2 Location, Function and Regulators
TAAR2 位置、功能和调节器的阐明
- 批准号:
10666759 - 财政年份:2023
- 资助金额:
$ 67.55万 - 项目类别:
Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease
结构工程呋喃脂肪酸用于治疗血脂异常和心血管疾病
- 批准号:
10603408 - 财政年份:2023
- 资助金额:
$ 67.55万 - 项目类别:
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 67.55万 - 项目类别:
PPARdelta receptors and alcohol use phenotypes
PPARδ 受体和饮酒表型
- 批准号:
10682348 - 财政年份:2023
- 资助金额:
$ 67.55万 - 项目类别: